MET and cancer: For patients with acquired resistance to EGFR TKIs caused by upregulation or amplification of MET, it may be beneficial to treat with a combination of inhibitors of both MET and EGFR, as this has been shown to have a synergistic inhibitory effect on the proliferation of cancer cells [2,21,22].